TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06821945: A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

Sponsor: Boryung Pharmaceutical Co., Ltd · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT06821945 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06821945 Rescue Dossier →